<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01019941</url>
  </required_header>
  <id_info>
    <org_study_id>CKD-810_PK_phase I</org_study_id>
    <nct_id>NCT01019941</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of CKD-810 and Taxotere to Treat Patient With Advanced Solid Cancer</brief_title>
  <acronym>126ASC08Q</acronym>
  <official_title>Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics of Docetaxel Between Two Docetaxel Products, CKD-810 and Taxotere Inj., in Patients With Advanced Solid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and the pharmacokinetic characteristics of
      docetaxel between two docetaxel products in patients with advanced solid cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III study designed to evaluate the pharmacokinetic characteristics of
      docetaxel between two docetaxel products in patients with advanced solid cancer. This study
      will also assess the safety of the docetaxel in advanced solid cancer patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of CKD-810 and Taxotere inj.</measure>
    <time_frame>2 Cycles</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of CKD-810 and Taxotere inj.</measure>
    <time_frame>2 Cycles</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Advanced Solid Cancers</condition>
  <arm_group>
    <arm_group_label>1st cycle:CKD-810 -&gt; 2nd cycle:Taxotere inj.</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1st cycle:Taxotere inj.-&gt; 2nd cycle:CKD-810</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-810, Taxotere inj.</intervention_name>
    <description>Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.</description>
    <arm_group_label>1st cycle:CKD-810 -&gt; 2nd cycle:Taxotere inj.</arm_group_label>
    <other_name>Docetaxel anhydrous, Docetaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-810, Taxotere inj.</intervention_name>
    <description>Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, Taxotere inj. 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.</description>
    <arm_group_label>1st cycle:Taxotere inj.-&gt; 2nd cycle:CKD-810</arm_group_label>
    <other_name>Docetaxel anhydrous, Docetaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is greater than 18 years of age

          -  Advanced solid tumor

               -  locally advanced or metastatic breast cancer which docetaxel alone therapy was
                  adequate

               -  locally advanced or metastatic non-small cell lung cancer which docetaxel alone
                  therapy was adequate

               -  locally advanced or metastatic other malignant tumor which docetaxel alone
                  therapy was adequate

          -  Patient has a life expectancy of at least 3 months

          -  Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

          -  Absolute neutrophil count ≥ 1,500/㎣

          -  Platelet count ≥ 100,000/㎣

          -  Hemoglobin ≥ 9.0g/dL

          -  Total Bilirubin ≤ 1.5 X ULN

          -  Alkaline Phosphatase ≤ 2.5 X ULN

          -  AST/ALT ≤ 2.0 X ULN

          -  Serum creatinine ≤ 1.5 X ULN or Creatinine clearance ≥ 60mL/min(Cockcroft equation)

          -  Patients should voluntarily sign a written informed consent before study entry

        Exclusion Criteria:

          -  If present, any active bacterial infection that have to parenteral antibiotic therapy.
             Patients may be included if their infection has resolved to totally or controlled
             state

          -  Brain metastasis with neurologic symptom

          -  History of unstable cardiac arrhythmia, congestive heart failure or myocardial
             infarction within 6 months

          -  Known to test positive for HIV or hepatitis B or C

          -  Use of inducers or inhibitors of CYP3A4 within 2 weeks prior to the first dose of
             study medication. (Patients may be included if the patients who need to intake the
             medication such as cimetidine was keep the same dose continuously at 1 cycle and 2
             cycle)

          -  Peripheral neuropathy ≥ Grade 2

          -  known resistant or uncontrolled severe hypersensitivity to docetaxel

          -  History of hypersensitivity reaction to Polysorbate 80

          -  The female patients of pregnancy, breast feeding or childbearing potential. And the
             patients has not laboratory result or the result was a positive serum pregnancy test,
             also Patients (M/F) with reproductive potential not implementing adequate
             contraceptive measurements. (In case of menopausal women, keeping menopause at least
             12 months. All sexually active male patients must agree to use adequate methods of
             birth control throughout the study)

          -  Administration of any other tumor therapy, including chemotherapy, radiotherapy, and
             immunotherapy within 4 weeks before the beginning of study treatment. Patients may be
             included if the radiotherapy was conducted to relieve symptoms and that symptoms
             recovered to grade 1

          -  treated with any investigational drugs within 4 weeks before the beginning of study
             treatment

          -  Must be treated concurrent administration of other anti-cancer medicine

          -  Not able to participate to the study, at the discretion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JH Kang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Inchon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic university of KOREA, Seoul ST. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongsan Medical Center, Keimyung University</name>
      <address>
        <city>Taegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeoungnam University Hospital</name>
      <address>
        <city>Taegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <last_update_submitted>December 15, 2010</last_update_submitted>
  <last_update_submitted_qc>December 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jin Kim</name_title>
    <organization>Chong Kun Dang</organization>
  </responsible_party>
  <keyword>Docetaxel</keyword>
  <keyword>CKD-810</keyword>
  <keyword>Taxotere inj.</keyword>
  <keyword>Advanced Solid cancer</keyword>
  <keyword>Pharmacokinetic evaluation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

